Teva to collaborate with Fosun Pharma for TEV-56278
Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed …
-
-
NextCure and Simcere partner to develop SIM0505 for solid tumours
NextCure has entered a strategic partnership with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, to develop SIM0505, a new …
-
Supernus makes depression drug play with $795m Sage buyout
Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals. According …
-
FDA approves MSD’s Keytruda to treat head and neck cancer
MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for …
-
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in …
-
Ethris and Thermo Fisher partner on mRNA solutions
Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution …
-
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June to 15 June in Milan, …
-
NICE approves GSK’s belantamab mafodotin for blood cancer
The National Health Service (NHS) England is set to become the first health system globally to offer the "Trojan horse" …
-
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth …
-
Myasthenia gravis market to reach $10.3bn across 7MM by 2034
The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the …
-
Bharat Biotech acquires licence for GSK’s Shigella vaccine development
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income …
-
The long road to acceptance: The slow adoption of ion chromatography in the pharmaceutical industry
Introduction Ion chromatography (IC), a highly sensitive technique for separating and quantifying ionic species, was introduced in the 1970s and marketed …
-
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults
The US Food and Drug Administration (FDA) has expanded approval of Moderna’s respiratory syncytial virus (RSV) vaccine to include younger …
-
Debiopharm and Alkyon link for radioligand therapies development
Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted radioligand therapies (RLTs). The partnership …
-
FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric …
